Pharma Bio Services (PBSV) AI Stock Analysis

• Market Cap: $11.22M
• Dividend Yield: N/A
• Average Volume (3M): 2.53K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.16
• Revenue Growth: -14.75%
• EPS Growth: 89.89%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.01
• Shares Outstanding: 22,904,491
• 10 Day Avg. Volume: 1,930
• 30 Day Avg. Volume: 2,531
• PEG Ratio: 1.42
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 1.38
• P/FCF Ratio: -55.94
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.01
• Enterprise Value/Ebitda: -25.94
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.11
• Revenue Forecast (FY): $12.00M

• Rating: 49 Neutral
• Price Target: $0.59 ▲(9.44% Upside)
• Action: Reiterated Date: 01/31/26
• Date: Action: Reiterated 01/31/26

The score is held back primarily by deteriorated operating performance and recent negative operating/free cash flow, despite a conservatively levered balance sheet. Technicals are modestly supportive with price trading above key moving averages, but valuation is constrained by a negative P/E and no dividend data.

Positive Factors

Strong Balance Sheet

A strong balance sheet with high equity and low leverage provides financial stability and reduces risk, supporting long-term operations.

Strategic Partnerships

Strategic partnerships enhance service offerings and market reach, potentially driving long-term revenue growth and competitive advantage.

EPS Growth

Significant EPS growth indicates improved profitability and operational efficiency, which can enhance investor confidence and support future growth.

Negative Factors

Declining Revenue

Declining revenue reflects potential market challenges and could impact the company's ability to invest in growth and innovation.

Negative Cash Flow

Negative cash flow highlights liquidity issues, which can limit the company's ability to fund operations and strategic initiatives long-term.

Low Profitability

Low profitability suggests challenges in cost management and pricing power, potentially affecting long-term financial health and competitiveness.

Pharma Bio Services Business Overview & Revenue Model

Company Description

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

How the Company Makes Money

PBSV generates revenue through a multi-faceted business model that includes service fees for clinical trial management, consulting services, and regulatory submissions. Key revenue streams consist of project-based contracts with pharmaceutical companies, retainer agreements for ongoing consulting services, and performance-based incentives tied to the successful completion of clinical trials. Additionally, PBSV has established strategic partnerships with research institutions and healthcare organizations, enhancing its service offerings and expanding its market reach, which further contributes to its financial performance.

Pharma Bio Services Financial Statement Overview

Summary

Mixed fundamentals: a strong, low-leverage balance sheet supports flexibility, but operating results have weakened (material revenue decline since 2020), profitability has been inconsistent, and operating/free cash flow turned negative in 2024–2025. The 2025 improvement (narrower loss and slightly positive EBITDA) is a positive, but not yet reflected in cash generation.

Income Statement

Operating performance has deteriorated meaningfully: revenue fell from ~$21.6M (2020) to ~$9.0M (2025), with a sharp drop shown in 2025. Profitability has been volatile—profitable in 2020, 2022, and 2023, but losses in 2021, 2024, and a small net loss in 2025. A key positive is the improvement in 2025 versus 2024 (loss narrowed materially and EBITDA turned slightly positive), but the overall trend is weaker scale and inconsistent earnings power.

Balance Sheet

The balance sheet appears conservatively levered, with very low debt relative to equity across the period (debt-to-equity stayed low, including ~0.01 in 2024). Total debt has also come down substantially versus 2020 levels, supporting financial flexibility. The main drawback is that equity and assets have trended lower since 2020, and recent losses (2024–2025) reduce the cushion over time if not reversed.

Cash Flow

Cash generation weakened sharply: operating cash flow and free cash flow were positive in 2020–2023, but turned negative in 2024 and remained negative in 2025. This shift suggests the business is currently consuming cash rather than funding itself internally. While 2024–2025 losses help explain the pressure, the inability to convert operations into cash recently is a notable risk until profitability and working-capital dynamics stabilize.

Breakdown	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Jan 2022
Income Statement
Total Revenue	9.00M	9.51M	16.98M	19.40M	20.12M
Gross Profit	2.91M	2.52M	5.07M	4.88M	5.36M
EBITDA	134.81K	-1.11M	1.31M	1.23M	-3.78M
Net Income	-100.46K	-777.62K	1.31M	1.01M	-2.09M
Balance Sheet
Total Assets	13.65M	16.29M	19.90M	20.65M	23.92M
Cash, Cash Equivalents and Short-Term Investments	10.85M	12.75M	14.98M	14.46M	17.47M
Total Debt	28.83K	194.03K	346.51K	487.36K	617.42K
Total Liabilities	1.74M	2.58M	3.78M	4.09M	5.01M
Stockholders Equity	11.91M	13.72M	16.13M	16.56M	18.91M
Cash Flow
Free Cash Flow	-221.53K	-726.44K	1.88M	573.19K	794.00K
Operating Cash Flow	-214.89K	-566.70K	1.89M	592.46K	804.84K
Investing Cash Flow	-1.47M	-1.36M	-4.22M	-19.27K	1.30M
Financing Cash Flow	-1.75M	-1.73M	-1.76M	-3.53M	-1.75M

Pharma Bio Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.54
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Negative. The current price of 0.54 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.49, and above the 200-day MA of 0.49, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.43 is Neutral, neither overbought nor oversold. The STOCH value of -137.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBSV.

Pharma Bio Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PBSV	49 Neutral	$11.22M	-111.36	-0.66%	―	-14.75%	89.89%
ZCMD	43 Neutral	$5.51M	-1.11	-8.96%	―	-24.64%	92.19%
HCTI	41 Neutral	$3.13M	―	-182.56%	―	-21.88%	68.40%
VSEE	38 Underperform	$15.96M	-0.48	―	―	187.24%	82.90%